// App-Quantinova.ai

105 : Hybrid capture-based next-generation sequencing (HC NGS) in melanoma to identify markers of response to anti-PD-1/PD-L1.

Researchers

Presenter

  • Douglas Buckner Johnson

Principal Investigators

  • Matthew J. Rioth

  • Erik Yusko

  • Riley Ennis

  • David Fabrizio

  • Joel R. Greenbowe

  • Siraj Mahamed Ali

  • Dennie T Frederick

  • Igor Puzanov

  • Justin M. Balko

  • Justin Cates

  • Jeffrey S. Ross

  • Harlan Robins

  • Vincent A. Miller

  • Phil Stephens

  • Ryan J. Sullivan

  • Jeffrey Alan Sosman

  • Christine Marie Lovly

Medical Centers

  • Vanderbilt University, Nashville, TN

  • Foundation Medicine, Inc, Cambridge, MA

  • Vanderbilt-Ingram Cancer Center, Nashville, TN

  • Adaptive Biotechnologies Corporation, Seattle, WA

  • Foundation Medicine, Inc., Boston, MA

  • UT Southwestern, Dallas, TX

  • Vanderbilt University Medical Center, Nashville, TN

  • Foundation Medicine, Inc, Cambridge, MA

  • Massachusetts General Hospital, Boston, MA

Locations

  • United States

Companies

  • Foundation Medicine,

  • Adaptive Biotechnolo

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

Biomarkers

  • Programmed death-ligand 1

  • T-cell receptor

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved